Skip to content
lifestyle.ribbon.co
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Opus Genetics, Inc.
Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
November 10, 2026
Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
November 5, 2026
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
November 3, 2026
Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 2, 2026
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
October 29, 2026
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
October 21, 2026
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
October 16, 2026
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
October 15, 2026
Opus Genetics to Present at the Chardan Annual Healthcare Conference
October 13, 2026
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
September 9, 2026
1
2
Next Page
→